Online inquiry

IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6487MR)

This product GTTS-WQ6487MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ6487MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12170MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-009
GTTS-WQ6011MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ6748MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DS 992
GTTS-WQ14675MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SCT-400
GTTS-WQ5794MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ15065MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ608MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ8238MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HLX-06
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW